Patents by Inventor Norbert Beier

Norbert Beier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110224302
    Abstract: Novel difluorophenyldiacylhydrazide derivatives of the formula I, in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in claim 1, are kinase inhibitors and can be used for the treatment of diseases and complaints such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in any type of fibroses, inflammatory processes, tumours and tumour diseases
    Type: Application
    Filed: November 2, 2009
    Publication date: September 15, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Thomas Fuchss, Ulrich Graedler, Norbert Beier, Rolf Gericke, Florian Lang
  • Publication number: 20110190355
    Abstract: Novel heterocyclic indazole derivatives of the formula (I), in which L, Q, R, X, Y, R3, R4 and R5 have the meanings indicated in Claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.
    Type: Application
    Filed: April 18, 2008
    Publication date: August 4, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Markus Klein, Norbert Beier
  • Publication number: 20110139654
    Abstract: Novel oxadiazole derivatives of the formula (I), in which R, R?, Y, X1, X2 and X3 have the meanings indicated in claim 1, are kinase inhibitors and can be used for the treatment of diseases and conditions such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, in general in all types of fibroses, inflammatory processes, tumours and tumour diseases.
    Type: Application
    Filed: July 9, 2009
    Publication date: June 16, 2011
    Inventors: Markus Klein, Norbert Beier, Florian Lang
  • Publication number: 20110060051
    Abstract: The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-Methyl-4,5-di-(methylsulfonyI)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of Type II diabetes mellitus, the Metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of ?-cell compensation.
    Type: Application
    Filed: April 11, 2009
    Publication date: March 10, 2011
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Norbert Beier, Wolfgang Scholz, Ulrich Betz, Marian Braendle
  • Publication number: 20110060050
    Abstract: The present invention relates to a compound of the formula I, Ia and Ib, and its pharmaceutically usable tautomers, salts, stereoisomers and the enantiomers, including mixtures thereof in all ratios.
    Type: Application
    Filed: February 17, 2009
    Publication date: March 10, 2011
    Applicant: Merck Patent GmbH
    Inventors: Thomas Fuchss, Rolf Gericke, Norbert Beier, Florian Lang, Phillipp Lang, Karl Lang
  • Patent number: 7884126
    Abstract: The invention relates to novel indazole derivatives as cited in claim 1, which are inhibitors of CHK1, CHK2 and SGK kinases and can be used to treat cancer and other diseases.
    Type: Grant
    Filed: January 10, 2007
    Date of Patent: February 8, 2011
    Assignee: Merck Patent GmbH
    Inventors: Markus Klein, Rolf Gericke, Werner Mederski, Norbert Beier, Florian Lang
  • Publication number: 20110028414
    Abstract: Novel compounds of the formula (I), in which X has the meaning indicated in Patent Claim 1, are suitable as antidiabetics.
    Type: Application
    Filed: March 17, 2009
    Publication date: February 3, 2011
    Inventors: Christos Tsaklakidis, Norbert Beier
  • Patent number: 7872039
    Abstract: Novel 3-aminoindazoles of the formula (I) are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibrosis and inflammatory processes of any type.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: January 18, 2011
    Assignee: Merck Patent Gesellschaft
    Inventors: Dieter Dorsch, Lars Thore Burgdorf, Rolf Gericke, Norbert Beier, Werner Mederski, Florian Lang
  • Publication number: 20110009437
    Abstract: Novel heterocyclic compounds of the formula I wherein D is wherein R1, R2, E?, E?, E??, Y?, Y?, G?, G?, G?? and G?? have the meaning of claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.
    Type: Application
    Filed: February 3, 2009
    Publication date: January 13, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Lars Thore Burgdorf, Stefan Bender, Christoph Saal, Christine Charon, Norbert Beier
  • Publication number: 20110009455
    Abstract: The present invention relates to novel compounds of general formula (I) and uses thereof. The present invention relates to novel compounds of general formula (I) for use as glucokinase activators in the treatment of diabetes and obesity.
    Type: Application
    Filed: February 5, 2009
    Publication date: January 13, 2011
    Applicant: Merck Patent Gesellschaft
    Inventors: Christoph Saal, Lars Burgdorf, Ulrich Emde, Norbert Beier, Johannes Gleitz, Christine Charon
  • Publication number: 20100331346
    Abstract: Novel heterocyclic compounds of the formula I in which R1, R2, R2?, R2?, R3, R4, R5, R6, R7 and R8 have the meanings indicated in Claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.
    Type: Application
    Filed: December 23, 2008
    Publication date: December 30, 2010
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Stefan Bender, Lars Thore Burgdorf, Ulrich Emde, Norbert Beier, Johannes Gleitz, Christine Charon
  • Publication number: 20100331338
    Abstract: Novel compounds of the Formula (I) in which R1, R2, R3, and R4 have the meanings indicated in Claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Type 1 and 2, obesity, neuropathy and/or nephropathy.
    Type: Application
    Filed: February 2, 2009
    Publication date: December 30, 2010
    Applicant: Merck Patent GMBH
    Inventors: Lars Burgdorf, Ulrich Emde, Johannes Gleitz, Norbert Beier, Christine Charon
  • Publication number: 20100305142
    Abstract: Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Patent Claim (1), are suitable as antidiabetics.
    Type: Application
    Filed: September 27, 2007
    Publication date: December 2, 2010
    Inventors: Markus Klein, Rolf Gericke, Norbert Beier, Bertram Cezanne, Christos Tsaklakidis, Werner Mederski
  • Publication number: 20100249151
    Abstract: Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5, R6 and X7 have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.
    Type: Application
    Filed: September 13, 2008
    Publication date: September 30, 2010
    Applicant: MERCK PATENT GESELLSCHAFT BESCHRANKTER HAFTUNG
    Inventors: Markus Klein, Werner Mederski, Christos Tsaklakidis, Norbert Beier
  • Publication number: 20100216794
    Abstract: Novel heterocyclic compounds of the formula I in which R1, R2, R3, R4 and D have the meanings indicated in claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.
    Type: Application
    Filed: August 13, 2008
    Publication date: August 26, 2010
    Inventors: Lars Thore Burgdorf, Norbert Beier, Johannes Gleitz, Christine Charon, Daniel Cravo
  • Publication number: 20100210690
    Abstract: Novel heterocyclic compounds of the formula I in which R1, R2, R3, R4, R5, R6, R7, Alk and D have the meanings indicated in claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.
    Type: Application
    Filed: September 9, 2008
    Publication date: August 19, 2010
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Lars Thore Burgdorf, Norbert Beier, Johannes Gleitz, Ulrich Emde, Christine Charon, Denis Carniato
  • Patent number: 7776920
    Abstract: Novel mandelic hydrazides of the formula (I), in which R1-R11 have the meanings indicated in claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: August 17, 2010
    Assignee: Merck Patent GmbH
    Inventors: Rolf Gericke, Markus Klein, Werner Mederski, Norbert Beier, Florian Lang
  • Patent number: 7767716
    Abstract: Novel acyl hydrazides of the formula (I), in which R1-R9 have the meanings indicated in claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibroses and inflammatory processes of any type.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: August 3, 2010
    Assignee: Merck Patent GmbH
    Inventors: Rolf Gericke, Dieter Dorsch, Werner Mederski, Markus Klein, Norbert Beier, Florian Lang
  • Publication number: 20100063115
    Abstract: Novel aminoindazolylurea derivatives of the formula (I), in which L, X, Y, R3, R4 and R5 have the meanings indicated in Claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.
    Type: Application
    Filed: December 11, 2007
    Publication date: March 11, 2010
    Inventors: Markus Klein, Norbert Beier
  • Publication number: 20100035915
    Abstract: Novel compounds of the formula (I), in which X, Y, R, R1, R1, R1?, R2, R2?, R3, R4, R4?, R5 and n have the meanings indicated in patent claim 1, are suitable as antidiabetics.
    Type: Application
    Filed: November 17, 2007
    Publication date: February 11, 2010
    Applicant: Merck Patent Gesellschaft
    Inventors: Werner Mederski, Norbert Beier, Lars Thore Burgdorf, Rolf Gericke, Markus Klein, Christos Tsaklakidis